GLP1R
Gene15 papers2 findingsHGNC 4324NCBI Gene 2740Taxon 9606
- Human trial6
- Humans4
Effects
2Barrett's oesophagus
no changein silico1OR 0.96
1 study
Barrett's oesophagus
no changein silico1OR 0.96
GLP1R has no effect on Barrett's oesophagus in silico (OR 0.96, 95% CI 0.47-1.96).
“For the Barrett's oesophagus/adenocarcinoma endpoint, estimates were near the null for both receptors (GLP-1R 0.96, 0.47-1.96; GIPR 1.00, 0.42-2.37)”
In silico
Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study · Biomedicines · 24 Aug 2026
Gastro-oesophageal reflux disease
no changein silico1OR 0.97
1 study
Gastro-oesophageal reflux disease
no changein silico1OR 0.97
GLP1R has no effect on gastro-oesophageal reflux disease in silico (OR 0.97, 95% CI 0.85-1.11).
“Genetically proxied GLP-1 receptor expression was not associated with reflux disease (odds ratio 0.97, 95% confidence interval 0.85-1.11)”
In silico
Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study · Biomedicines · 24 Aug 2026
Latest
15Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study
Semaglutide curbs kidney vascular resistance and fibrosis
In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to…In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to placebo.
Survodutide reduces weight in adults with diabetes and obesity
Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties
Retatrutide reduces weight and pain in adults with obesity
Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
A cross-ancestry Mendelian randomization study of up to 1,812,017 individuals linked genetically proxied GLP-1 receptor agonist exposure to reduced…A cross-ancestry Mendelian randomization study of up to 1,812,017 individuals linked genetically proxied GLP-1 receptor agonist exposure to reduced risk of stroke and Alzheimer disease.
Genetically proxied GIP pathway links to lower fracture risk
Scaled to lower BMI, genetically proxied GIP-GIPR perturbation tracked with lower odds of major osteoporotic fractures (OR 0.80) and spine-and-hip…Scaled to lower BMI, genetically proxied GIP-GIPR perturbation tracked with lower odds of major osteoporotic fractures (OR 0.80) and spine-and-hip fractures (OR 0.68).